In silico analysis of SARS-CoV-2 papain-like protease potential inhibitors

被引:0
|
作者
Elseginy, Samia A. [1 ]
Anwar, Manal M. [2 ]
机构
[1] Natl Res Ctr, Green Chem Dept, Chem Ind Res Div, POB 12622, Cairo, Egypt
[2] Natl Res Ctr, Therapeut Chem Dept, Cairo 12622, Egypt
关键词
RESPIRATORY-SYNDROME-CORONAVIRUS; COV; SARS; IDENTIFICATION; GROMACS; ENZYMES;
D O I
10.1039/d1ra07845c
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The emergent outbreak caused by severe acute respiratory syndrome coronavirus 2 continues spreading and causing huge social and economic disruption. Papain-like protease (PLpro) has a crucial role in the cleavage of viral polyproteins, and disruption of host responses. PLpro is considered an important goal for the development of SARS-CoV-2 inhibitors. ZINC101291108 (lead 1) and ZINC16449029 (lead 2) were identified as potent SARS-CoV-2 PLpro inhibitors with IC50 values of 0.085 mu M and 0.063 mu M, respectively. Molecular dynamics simulations (MD) were carried out for lead 1, 2 and several reported SARS-CoV-2 inhibitors. Analysis results of the simulations confirmed the stability of both compounds and showed that they adopted two confirmations along the simulation period. The per-residue decomposition results revealed that the key residues involved in inhibitor binding were E167, P247, P248, Y264, Y268 and Q269. H-bond analyses showed H-bonds with G266 and N267 and salt bridges with G209 and Y273, which are essential for strengthening the substrate-binding pocket. Both inhibitors showed hydrophobic interactions with the S4 site and BL2 loop residues. The RMSD of the BL2 loop with the two inhibitors was investigated, and the results showed that the Y268 and Q269 BL2 loop residues moved outward to accommodate the large size of lead 2. The van der Waals interaction was the main energy contribution that stabilized lead 2, while van der Waals and electrostatic interactions were the main energy contributions stabilizing lead 1. Rational design strategies were suggested to replace the 2-(2-hydroxybenzylidene) hydrazine moiety with naphthalene or nitrobenzene at the P4 position of lead 2 and introduce polar substituents as aniline and benzoate groups at position P1 to enhance hydrophobic interactions and H-bonds, respectively.
引用
收藏
页码:38616 / 38631
页数:16
相关论文
共 50 条
  • [21] Hemi-Babim and Fenoterol as Potential Inhibitors of MPro and Papain-like Protease against SARS-CoV-2: An In-Silico Study
    Alzamami, Ahmad
    Alturki, Norah A.
    Alghamdi, Youssef Saeed
    Ahmad, Shaban
    Alshamrani, Saleh
    Asiri, Saeed A.
    Mashraqi, Mutaib M.
    [J]. MEDICINA-LITHUANIA, 2022, 58 (04):
  • [22] Structure-based design of SARS-CoV-2 papain-like protease inhibitors
    Jadhav, Prakash
    Huang, Bo
    Osipiuk, Jerzy
    Zhang, Xiaoming
    Tan, Haozhou
    Tesar, Christine
    Endres, Michael
    Jedrzejczak, Robert
    Tan, Bin
    Deng, Xufang
    Joachimiak, Andrzej
    Cai, Jianfeng
    Wang, Jun
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 264
  • [23] Insights for Future Pharmacology: Exploring Phytochemicals as Potential Inhibitors Targeting SARS-CoV-2 Papain-like Protease
    Jabeen, Jawaria
    Ahmed, Nabeel
    Shahzad, Zunaira
    Shahid, Maida
    Ahmad, Taseer
    [J]. FUTURE PHARMACOLOGY, 2024, 4 (03): : 510 - 540
  • [24] Targeting SARS-CoV-2 papain-like protease in the postvaccine era
    Ton, Anh-Tien
    Pandey, Mohit
    Smith, Jason R.
    Ban, Fuqiang
    Fernandez, Michael
    Cherkasov, Artem
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (11) : 906 - 919
  • [25] Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2
    Klemm, Theresa
    Ebert, Gregor
    Calleja, Dale J.
    Allison, Cody C.
    Richardson, Lachlan W.
    Bernardini, Jonathan P.
    Lu, Bernadine G. C.
    Kuchel, Nathan W.
    Grohmann, Christoph
    Shibata, Yuri
    Gan, Zhong Yan
    Cooney, James P.
    Doerflinger, Marcel
    Au, Amanda E.
    Blackmore, Timothy R.
    van der Heden van Noort, Gerbrand J.
    Geurink, Paul P.
    Ovaa, Huib
    Newman, Janet
    Riboldi-Tunnicliffe, Alan
    Czabotar, Peter E.
    Mitchell, Jeffrey P.
    Feltham, Rebecca
    Lechtenberg, Bernhard C.
    Lowes, Kym N.
    Dewson, Grant
    Pellegrini, Marc
    Lessene, Guillaume
    Komander, David
    [J]. EMBO JOURNAL, 2020, 39 (18):
  • [26] High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors
    Zang, Yi
    Su, Mingbo
    Wang, Qingxing
    Cheng, Xi
    Zhang, Wenru
    Zhao, Yao
    Chen, Tong
    Jiang, Yingyan
    Shen, Qiang
    Du, Juan
    Tan, Qiuxiang
    Wang, Peipei
    Gao, Lixin
    Jin, Zhenming
    Zhang, Mengmeng
    Li, Cong
    Zhu, Ya
    Feng, Bo
    Tang, Bixi
    Xie, Han
    Wang, Ming-Wei
    Zheng, Mingyue
    Pan, Xiaoyan
    Yang, Haitao
    Xu, Yechun
    Wu, Beili
    Zhang, Leike
    Rao, Zihe
    Yang, Xiuna
    Jiang, Hualiang
    Xiao, Gengfu
    Zhao, Qiang
    Li, Jia
    [J]. PROTEIN & CELL, 2023, 14 (01) : 17 - 27
  • [27] Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro
    Kiba, Yuka
    Tanikawa, Takashi
    Kitamura, Masashi
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2024, 47 (05) : 965 - 966
  • [28] SARS-CoV-2 Papain-Like Protease: Structure, Function and Inhibition
    Ullrich, Sven
    Nitsche, Christoph
    [J]. CHEMBIOCHEM, 2022, 23 (19)
  • [29] Supercomputing, Docking and Quantum Mechanics in Quest for Inhibitors of Papain-like Protease of SARS-CoV-2
    Sulimov, A., V
    Ilin, I. S.
    Kutov, D. C.
    Stolpovskaya, N., V
    Shikhaliev, Kh S.
    Sulimov, V. B.
    [J]. LOBACHEVSKII JOURNAL OF MATHEMATICS, 2021, 42 (07) : 1571 - 1579
  • [30] Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
    Tan, Haozhou
    Hu, Yanmei
    Jadhav, Prakash
    Tan, Bin
    Wang, Jun
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (11) : 7561 - 7580